Abrocitinib 100 mg Once Daily for Moderate-to-Severe Atopic Dermatitis: A Review of Efficacy and Safety, and Expert Opinion on Use in Clinical Practice

Abrocitinib 100 mg Once Daily for Moderate-to-Severe Atopic Dermatitis: A Review of Efficacy and Safety, and Expert Opinion on Use in Clinical Practice

Abstract Abrocitinib is a Janus kinase (JAK) 1-selective inhibitor approved for the treatment of moderate-to-severe atopic dermatitis (AD). Although specific dose recommendations for abrocitinib vary across regional product labels, abrocitinib 100 mg once daily is recommended as a starting and maint...

Full description

Bibliographic Details
Main Authors: Melinda J. Gooderham, Andrew E. Pink, Eric L. Simpson, Jonathan I. Silverberg, Erman Güler, Melissa Watkins
Format: Article
Language:English
Published: Adis, Springer Healthcare 2023-07-01
Series:Dermatology and Therapy
Subjects:
Abrocitinib
Clinical practice
Flexible dosing
JAK1-selective inhibitor
Moderate-to-severe atopic dermatitis
Oral systemic therapy
Online Access:https://doi.org/10.1007/s13555-023-00948-6

Similar Items

Similar Items